Henry Querfurth is a Neurology physician affiliated with Providence College. OpenAlex indexes 130 publications with 15,254 citations (h-index 51). By OpenAlex citation count, this profile ranks in the top 10% of Neurology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
736 Cambridge St
Brighton, MA 021352907
Telephone
617-789-2696Registry record last updated 18 Feb 2009.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20251 payment
- ABBVIE INC.Program year20251 payment
- Biohaven Pharmaceuticals, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
97.5%Cholinesterase Inhibitor55.3%Donepezil Hcl67%Galantamine Er22%Rivastigmine11%Part D<11 patientsN-methyl-D-aspartate Receptor Antagonist16%Memantine Hcl Er74%Memantine Hcl26%Part D<11 patients+ 7 more classes in this area
Cardiovascular
2.5%Beta blocker2.5%Propranolol Hcl Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 1993–2013 per NIH RePORTER. The latest:
- A Novel Insulin Pathway Agonist for Alzheimer's Disease
Medchem Partners, Llc
FY2013$147,729R41AG044871 - Beta-Amyloid &Cell Death Mechanisms in Skeletal Muscle
Caritas St. Elizabeth'S Medical Center
FY2005$276,806R01NS041373 - Beta-Amyloid &Cell Death Mechanisms in Skeletal Muscle
Caritas St. Elizabeth'S Medical Center
FY2004$276,806R01NS041373
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction
Communications Medicine
2023 - Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration
Molecular Neurodegeneration
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Brian Ott, MD
Providence College
Paul Disilvestro, MD
Providence College
Barry Sharaf, MD
Providence College
Sherwyn Schwartz
Providence College
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”